We were delighted to have the opportunity to speak with Indu Subramanian (Geffen School of Medicine, UCLA, and West Los Angeles Veterans Administration, Los Angeles, CA, USA) around the focus of her recently published article entitled: Synergy of pandemics-social isolation is associated with worsened Parkinson severity and quality of life, which was highlighted as a top abstract at the MDS Virtual Congress 2020.
1. What were the aims, design and outcome measures of your study? (0:06)
2. What were the findings of this study in terms of symptom severity and quality of life? (3:59)
3. What were the limitations of this study and what further studies would be useful? (5:58)
See also the 1st part of this interview here.
Disclosures: Dr Indu Subramanian has no financial or non-financial relationships or activities to declare in relation to this video interview.
Support: Interview and filming supported by Touch Medical Media.
Filmed as a highlight of the International Parkinson and Movement Disorder Society MDS Virtual Congress 2020.
Share this Video
Related Videos In Parkinson's Disease
Heinz Reichmann, EAN 2021: OPTIPARK Study Findings
We were delighted to meet with Heinz Reichmann (Technische Universität Dresden, Dresden, Germany) to discuss the key real world findings from the OPTIPARK study, investigating the use of Opicapone in the treatment of Parkinson’s disease. The abstract entitled: ‘Opicapone in Parkinson’s patients with motor fluctuations and complications of therapy at baseline: the OPTIPARK study’ was presented […]
Heinz Reichmann, EAN 2021: Levodopa-based Drugs in the Treatment of Parkinson’s Disease
We were delighted to meet with Heinz Reichmann (Technische Universität Dresden, Dresden, Germany) to discuss the use of levodopa-based drugs for managing Parkinson’s disease. The abstract entitled: ‘Opicapone in Parkinson’s patients with motor fluctuations and complications of therapy at baseline: the OPTIPARK study’ was presented at the 7th Congress of the European Academy of Neurology […]
Stephen Pasternak, AD/PD 2021: Phase 2 trial Investigating Ambroxol as a Treatment for Parkinson’s Disease Dementia
It was a great pleasure to speak with Stephen Pasternak (University of Western Ontario, Ontario, Canada) to discuss the phase 2 trial investigating ambroxol as a disease-modifying treatment for Parkinson’s Disease dementia. The abstract entitled ‘Ambroxol as a Disease-modifying Treatment for Parkinson’s Disease Dementia: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial’ was presented at The […]
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!